New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
06:16 EDTAGN, VRXAllergan upgraded to Outperform from Market Perform at Leerink
Leerink upgraded its rating on Allergan (AGN) shares to Outperform citing a compelling risk/reward profile following the recent pullback in shares. The firm believes Valeant's (VRX) takeover attempt is having little if any impact on Allergan's business. Leerink has a $184 price target for Allergan shares, which closed yesterday down $5.18 to $151.92.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
19:14 EDTVRXOn The Fly: After Hours Movers
Subscribe for More Information
18:27 EDTVRXSalix receives FDA Approval of Xifaxan for treatment of IBS-D
Subscribe for More Information
16:59 EDTVRXFDA approves Salix-marketed Xifaxan
The FDA approved Viberzi and Xifaxan, two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea, or IBS-D, in adult men and women. Xifaxan is marketed by Salix Pharmaceuticals, which was acquired by Valeant Pharmaceuticals. Reference Link
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information
10:29 EDTAGNAmerican Urological Association to hold an annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use